Mannkind Corp
MNKD
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.21B
Close$
$4.94
30% upside
Current Fair Value
30% upsideUndervalued by 30% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.21 Billion |
|---|---|
| Enterprise Value | $1.29 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.02 |
| Beta | 1.09 |
| Outstanding Shares | 308,267,000 |
Return
| Return on Equity | 40.40% |
|---|---|
| Return on Assets | -3.21% |
| Return on Invested Capital | 2.72% |
Valuation & Multiples
| P/E Ratio | -50.58 |
|---|---|
| PEG | 22.35 |
| Price to Sales | 3.8 |
| Price to Book Ratio | -3.8 |
| Enterprise Value to Revenue | 3.58 |
| Enterprise Value to EBIT | 77.99 |
| Enterprise Value to Net Income | -55 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | -2.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$105.38 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$108.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 153.17% |
|---|---|
| Total Calls | 500▼ 99.96% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.68%▼ 54.73% |
|---|---|
| Total Invested | $48.23M▼ 89.09% |
| Investors Holding | 65▼ 194.00% |
ESG Score
No data
About Mannkind Corp
233 employees
CEO: Michael Castagna MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder,...